Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $75.00 price target on the stock.

Aligos Therapeutics Trading Down 7.0 %

ALGS stock opened at $8.40 on Wednesday. The company’s 50 day moving average is $10.59 and its 200 day moving average is $13.44. The stock has a market cap of $656.12 million, a price-to-earnings ratio of -6.56 and a beta of 2.16. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.00) by $4.75. The company had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same quarter last year, the firm posted ($10.75) earnings per share. As a group, sell-side analysts forecast that Aligos Therapeutics will post -8.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

Hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC grew its holdings in shares of Aligos Therapeutics by 17.6% during the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after purchasing an additional 98,628 shares during the last quarter. Opaleye Management Inc. grew its stake in shares of Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after buying an additional 333,000 shares during the last quarter. Finally, Armistice Capital LLC increased its holdings in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after buying an additional 363,000 shares during the period. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).